24 unknown, 17 recruiting, 8 not yet recruiting, 5 active not recruiting. 64 Phase 2, 10 Phase 1, 2 Phase 3.
Follow PD-1 inhibitor: new trials by email Literature Review of PD-1 inhibitor trials Research Report on PD-1 inhibitor
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Oncolytic Virus Plus PD-1 Inhibitor to Patients With Advanced Pancreatic Cancer H101, Camrelizumab - Pancreatic Cancer | Phase 2 | Not yet recruiting | Fudan University | 30 | 2026-12-01 | 2025-08-07 |
| MRD and Imaging Guided Adaptive Neoadjuvant Therapy for Resectable NSCLC PD-1 inhibitor, Carboplatin, Nab-paclitaxel - Non-Small Cell Lung Cancer (NSCLC) | Phase 2 | Not yet recruiting | Peking University People's Hospital | 100 | 2026-11-01 | 2026-10-21 |
| A Phase II Study of Anlotinib + PD-1 Inhibitor vs. PD-1 Inhibitor Maintenance After First-Line Chemoimmunotherapy in Advanced ESCC (Esophageal Squamous Cell Carcinoma) anlotinib + PD-1 inhibitor, PD-1 inhibitor - Esophageal Cancer (EC) | Phase 2 | Recruiting | Sun Yat-sen University | 112 | 2026-10-12 | 2026-10-07 |
| Local Ablation Plus Systemic Therapy for Metachronous Liver and/or Lung Oligometastases From Nasopharyngeal Carcinoma CT-guided percutaneous local ablation, Gemcitabine, Cisplatin - Nasopharyngeal Carcinoma, Neoplasm Metastasis | Phase 2 | Not yet recruiting | Sun Yat-sen University | 138 | 2026-10-01 | 2026-09-17 |
| ctDNA-Guided Immunotherapy for dMMR/MSI-H Colon Cancer PD-1 inhibitor, CTLA-4 inhibitor, ctDNA/MRD testing - Colon Cancer, Deficient Mismatch Repair | Phase 2 | Recruiting | Fudan University | 23 | 2026-09-14 | 2026-09-25 |
| Serine/Glycine-Restricted Diet With Chemoradiotherapy for Rectal Cancer Serine/Glycine-Restricted Diet, CAPOX Chemotherapy, PD-1 Inhibitor - Locally Advanced Rectal Cancer (LARC) | Phase 1 / Phase 2 | Not yet recruiting | Xuelei Ma MD | 140 | 2026-08-31 | 2026-09-09 |
| Sintilimab Plus Gossypol Acetate in Advanced Colorectal Cancer Sintilimab, Gossypol Acetate - Advanced Colorectal Cancer | Phase 2 | Not yet recruiting | Peking University People's Hospital | 32 | 2026-07-15 | 2026-06-25 |
| A Study of Liposomal Irinotecan Plus 5-FU/LV HAIC With Lenvatinib and a PD-1 Inhibitor in Advanced ICC Hepatic Arterial Infusion Chemotherapy (HAIC) with Liposomal Irinotecan, 5-Fluorouracil, Leucovorin, Lenvatinib, PD-1 Inhibitor - Intrahepatic Cholangiocarcinoma | Phase 2 | Not yet recruiting | Tianjin Medical University Cancer Institute and Hospital | 30 | 2026-03-09 | 2026-02-25 |
| Hypofractionated Radiotherapy Plus Immunochemotherapy for Neoadjuvant Treatment of Gastroesophageal Junction Adenocarcinoma hypofractionated radiotherapy, PD-1 inhibitor, TS-1 - Gastroesophageal Junction Adenocarcinoma, Hypofractionated Radiotherapy | Phase 1 / Phase 2 | Recruiting | West China Hospital | 84 | 2025-11-18 | 2026-01-06 |
| Phase I/II Clinical Study of GT201 Injection as Monotherapy or in Combination With PD-1 Inhibitor for Advanced Solid Tumors GT201, IL-2, PD-1 inhibitor - Advanced Solid Tumors | Phase 1 / Phase 2 | Recruiting | Grit Biotechnology | 78 | 2025-11-01 | 2026-08-19 |
| Conversion Therapy Plus Surgery and Radiotherapy for Retroperitoneal Nodal Metastases in Gastric Cancer SOX regimen, CAPEOX regimen, PD-1 inhibitor - Gastric Adenocarcinoma, Stomach Neoplasms | Phase 2 | Recruiting | Jinbo Yue | 54 | 2025-10-01 | 2026-10-15 |
| Relmacabtagene Autoleucel Combined With Sintilimab for Relapsed/Refractory B-cell Lymphoma Autoleucel (Relmacabtagene Autoleucel), Sintilimab (PD-1 inhibitor) - Large B Cell Diffuse Lymphoma, Mantle Cell Lymphoma (MCL) | Phase 2 | Recruiting | Sun Yat-sen University | 30 | 2025-09-15 | 2026-01-21 |
| Hypofractionated Radiotherapy Combined With Immunochemotherapy for Conversion Treatment of Gastroesophageal Junction Adenocarcinoma hypofractionated radiotherapy, SOX Chemotherapy, PD-1 inhibitor - Gastroesophageal Junction Adenocarcinoma, Hypofractionated Radiotherapy | Phase 1 / Phase 2 | Recruiting | West China Hospital | 88 | 2025-09-15 | 2025-11-28 |
| A Clinical Study Evaluating the Efficacy and Safety of Disitamab Vedotin Combined With PD-1 Inhibitor and Radiotherapy as Bladder-preserving Therapy in Patients With Localized HER2-high Expressing Muscle-invasive Bladder Urothelial Carcinoma Following Maximal Transurethral Resection Disitamab Vedotin, PD-1 inhibitor, radiotherapy - Bladder (Urothelial, Transitional Cell) Cancer | Phase 2 | Not yet recruiting | RenJi Hospital | 45 | 2025-09-01 | 2025-08-26 |
| The Efficacy and Safety of Glofitamab in Combination With PD-1 Antibody and Lenalidomide in Patients With Relapsed/Refractory Large B-cell Lymphoma (LBCL) With TP53 Aberrations: A Prospective, Multicenter, Phase II Clinical Study Glofitamab, PD-1 Inhibitor, Lenalidomide - Large B-cell Lymphoma, TP53 | Phase 2 | Recruiting | The First Affiliated Hospital with Nanjing Medical University | 24 | 2025-09-01 | 2025-11-20 |
| Utidelone Capsule Combined With Fluoropyrimidine- and Platinum-containing Therapy in First-line Treatment of Patients With Gastric or Gastroesophageal Junction Adenocarcinoma Utidelone Capsule, Fluoropyrimidine- and Platinum-containing Therapy, Oxaliplatin - Gastric or Gastroesophageal Junction Adenocarcinoma | Phase 2 / Phase 3 | Recruiting | Beijing Biostar Pharmaceuticals Co., Ltd. | 778 | 2025-08-28 | 2025-11-25 |
| PROPHET Study: ctDNA-Guided Personalized Induction Immunochemotherapy for NSCLC PD-1 inhibitor, Platinum Doublet - Non-small Cell Lung Cancer (NSCLC) | Phase 2 | Recruiting | Sun Yat-sen University | 83 | 2025-05-10 | 2025-05-23 |
| A Study to Investigate the Safety, Pharmacokinetics, and Preliminary Effectiveness of GSK4418959 Alone or in Combination With Other Anti-cancer Agents in Participants With Solid Tumors GSK4418959, PD-1 inhibitor - Neoplasms, Colorectal, Solid Tumor | Phase 1 / Phase 2 | Active not recruiting | GlaxoSmithKline | 14 | 2024-12-13 | 2026-02-02 |
| ARTA-based Chemo-free Bridging/Maintenance Therapy in CAR-T Treatment for High-Risk R/R B-NHL Ineligible for HDCT and ASCT All-trans retinoic acid, zanubrutinib, radiotherapy - B-cell Non Hodgkin Lymphoma | Phase 2 | Not yet recruiting | Ruijin Hospital | 35 | 2024-12-01 | 2024-11-01 |
| Polarized Dendritic Cell (aDC1) Based Treatment, Interferon Alpha-2, Rintatolimod, and Celecoxib for the Treatment of HLA-A2+ Refractory Melanoma Alpha-type-1 Polarized Dendritic Cells, Celecoxib, PD-1 Ligand Inhibitor - HLA-A2 Positive Cells Present, Refractory Melanoma | Phase 2 | Terminated | Roswell Park Cancer Institute | 1 | 2024-11-13 | 2026-02-25 |
Showing 20 of 64. Sign in to see all of them.
Carcinoma, Non-Small-Cell Lung (7) · Neoplasms (4) · Carcinoma, Hepatocellular (3) · Colorectal Neoplasms (3) · Esophageal Neoplasms (3) · Head and Neck Neoplasms (3) · Nasopharyngeal Carcinoma (3) · Colonic Neoplasms (2) · Lung Neoplasms (2) · Lymphoma, B-Cell (2) · Lymphoma, Large B-Cell, Diffuse (2) · Melanoma (2) · Neoplasm Metastasis (2) · Neoplasm, Residual (2) · Rectal Neoplasms (2)
Sun Yat-sen University (12) · Hunan Cancer Hospital (4) · Tianjin Medical University Cancer Institute and Hospital (4) · BioAtla, Inc. (3) · Cancer Institute and Hospital, Chinese Academy of Medical Sciences (3) · Fudan University (3) · Fujian Cancer Hospital (2) · Peking Union Medical College Hospital (2) · Peking University People's Hospital (2) · RenJi Hospital (2) · Ruijin Hospital (2) · The First Affiliated Hospital of Nanchang University (2) · West China Hospital (2) · Amgen (1) · Beijing Biostar Pharmaceuticals Co., Ltd. (1)
China (51) · United States (11) · Spain (5) · Taiwan (4) · Hong Kong (3) · Australia (2) · Greece (2) · Italy (2) · Poland (2) · United Kingdom (2) · Belgium (1) · Canada (1) · Czechia (1) · Denmark (1) · France (1)
Aiping Zhou, M.D. (1) · Biao Zhu, PhD (1) · Binghao Li, Medical PhD (1) · Dehui Zou, Dr. (1) · Depei Wu, M.D. (1) · Dongsheng Zhang, PhD (1) · Gang Huang (1) · Hao Feng (1) · Hui Wang (1) · Igor Puzanov (1) · Jianyang Wang, MD (1) · Jiaolin Zhou, Ph.D (1) · Jie Chai, MD, PhD (1) · Jinbo Yue, MD, PhD (1)
PMID 32067509, PMID 35399603, PMID 35703113, PMID 38261958, PMID 38579194, PMID 39038917, PMID 39462179, PMID 40251674, PMID 40882625, PMID 41654611, PMID 42320551, PMID 42332718
P01CA234212 (1)